Abstract

Doc number: 1

Abstract: Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white blood cells are an integral part of the ADCC pathway. Differential response to therapeutic mAbs has been reported to correlate with specific polymorphisms in two of these genes: FCGR2A (H131R) and FCGR3A (V158F). These polymorphisms are associated with differential affinity of the receptors for mAbs. This review critically examines the current evidence for genotyping the corresponding single nucleotide polymorphisms (SNPs) to predict response to mAbs in patients with cancer.

Details

Title
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
Author
Mellor, James D; Brown, Michael P; Irving, Helen R; Zalcberg, John R; Dobrovic, Alexander
Pages
1
Publication year
2013
Publication date
2013
Publisher
BioMed Central
e-ISSN
17568722
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/1756-8722-6-1
ProQuest document ID
1271588316
Copyright
© 2013 Mellor et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.